Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

GK Dresser, JD Spence, DG Bailey - Clinical pharmacokinetics, 2000 - Springer
Drug interactions occur when the efficacy or toxicity of a medication is changed by
administration of another substance. Pharmacokinetic interactions often occur as a result of …

Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors

D Zeltser, D Justo, A Halkin, V Prokhorov, K Heller… - Medicine, 2003 - journals.lww.com
Numerous medications, including drugs prescribed for noncardiac indications, can lead to
QT prolongation and trigger torsade de pointes. Although this complication occurs only …

Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions

DK Wysowski, A Corken, H Gallo-Torres… - Official journal of the …, 2001 - journals.lww.com
OBJECTIVE: To describe the postmarketing safety data used in the risk assessment of
cisapride and to summarize the regulatory actions of the Food and Drug Administration …

Seizure versus syncope

A McKeon, C Vaughan, N Delanty - The lancet neurology, 2006 - thelancet.com
One of the most common but difficult management problems in medicine is that of patients
who present with a paroxysmal loss of consciousness. All too often the underlying diagnosis …

Drug Interactions with Cisapride.

EL Michalets, CR Williams - Clinical pharmacokinetics, 2000 - search.ebscohost.com
Cisapride, a prokinetic agent, has been used for the treatment of a number of
gastrointestinal disorders, particularly gastro-oesophageal reflux disease in adults and …

Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome

C TeBay, AP Hill, MJ Windley - Biophysical Reviews, 2022 - Springer
Drug-induced long QT syndrome (diLQTS) is the phenomenon by which the administration
of drugs causes prolongation of cardiac repolarisation and leads to an increased risk of the …

The interaction of diltiazem with simvastatin

O Mousa, DC Brater, KJ Sundblad… - Clinical Pharmacology & …, 2000 - Wiley Online Library
Background Simvastatin is an inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐
CoA) reductase that is used as a cholesterol‐lowering agent and is metabolized by …

The role of cisapride in the treatment of pediatric gastroesophageal reflux

Y Vandenplas, DC Belli, A Benatar… - Journal of pediatric …, 1999 - journals.lww.com
Background: Cisapride is a gastrointestinal prokinetic agent that is used worldwide in the
treatment of gastrointestinal motility-related disorders in premature infants, full-term infants …

Pathophysiology and pharmacological treatment of gastroesophageal reflux disease

M Storr, A Meining, HD Allescher - Digestive Diseases, 2000 - karger.com
Gastroesophageal reflux disease (GERD) is one of the most common diagnoses in a
gastroenterologist's practice. Gastroesophageal reflux describes the retrograde movement …

Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance

M Perrio, S Voss, SAW Shakir - Drug Safety, 2007 - Springer
Abstract Introduction: The Bradford Hill criteria are a widely used, useful tool for the
assessment of biomedical causation. We have examined their application to …